Chlorhexidine ( DrugBank: Chlorhexidine )

2 diseases

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	1
299	Cystic fibrosis	3

86. Pulmonary arterial hypertension

Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000005438	2011/04/01	14/04/2011	prospective intervention study of prevention of infections by chlorhexidine-impregnated sponge dressings for patients with tunneled central venous catheters		patients with pulmonary arterial hypertension	Use of chlorhexidine-impregnated sponge dressing during former 6 months Use of chlorhexidine-impregnated sponge dressing during latter 6 months	Department of cardiology, Keio University School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan

299. Cystic fibrosis

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03489629 (ClinicalTrials.gov)	April 3, 2018	29/3/2018	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	Cystic Fibrosis	Drug: Trimethoprim Sulfamethoxazole (TMP/SMX);Drug: Minocycline;Drug: Mupirocin;Drug: Chlorhexidine Gluconate;Behavioral: Environmental Decontamination	University of North Carolina, Chapel Hill	University of Washington;Cook Children's Medical Center;Indiana University;University of Michigan;University of Texas Southwestern Medical Center;St. Louis Children's Hospital	Recruiting	2 Years	45 Years	All	42	Phase 2	United States
2	NCT01594827 (ClinicalTrials.gov)	October 2012	7/5/2012	Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)	Persistent MRSA Eradication Protocol (PMEP)	Cystic Fibrosis	Drug: Inhaled Vancomycin;Drug: Placebo (Sterile Water);Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX);Drug: Doxycycline;Drug: Mupirocin Intranasal Creme;Drug: 4% chlorhexidine gluconate liquid skin cleanser	Johns Hopkins University	Case Western Reserve University;Cystic Fibrosis Foundation	Completed	12 Years	N/A	All	29	Phase 2	United States
3	NCT01349192 (ClinicalTrials.gov)	April 2011	4/5/2011	Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)	Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)	Cystic Fibrosis;Methicillin-resistant Staphylococcus Aureus	Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole;Drug: Minocycline;Drug: Mupirocin;Drug: chlorhexidine gluconate oral rinse;Drug: 2% Chlorhexidine solution wipes;Behavioral: Environmental Decontamination	University of North Carolina, Chapel Hill	CF Therapeutics Development Network Coordinating Center;Seattle Children's Hospital;Washington University School of Medicine;University of Washington;University of Colorado, Denver;Baylor College of Medicine;University of Alabama at Birmingham;Cook Children's Medical Center;University of Michigan;University of Florida;University of Texas Southwestern Medical Center;Children's Hospital Medical Center, Cincinnati;St. Louis Children's Hospital	Terminated	4 Years	45 Years	All	47	Phase 2	United States